Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos


Autoria(s): Silva-López,Raquel Elisa da
Data(s)

01/01/2010

Resumo

Leishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but HIV co-infection, chemotheraphy toxicity and lack of a vaccine are paramount difficulties. So, is necessary to study new Leishmania molecules and investigate the possibility to develop rational drugs using these molecules as targets. Leishmania express many peptidases during their life, and cysteine are the most abundant protease and many inhibitors were developed but failed to kill parasites. On the other hand, inhibitors of serine proteases killed promastigotes, indicating the possibility of these enzymes to be important targets in the development of anti-Leishmania drugs.

Formato

text/html

Identificador

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422010000700022

Idioma(s)

pt

Publicador

Sociedade Brasileira de Química

Fonte

Química Nova v.33 n.7 2010

Palavras-Chave #proteases #Leishmania #chemotheraphy
Tipo

journal article